RankAlpha logo
Back to Rankings

INCY

IncyteB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
View Chart
Current thesis
The post-earnings bull read is that Incyte delivered a clean quarter, kept 2026 guidance intact, showed broad commercial growth beyond Jakafi, and paired that with multiple dated regulatory and pipeline milestones. The median analyst target in the packet, $108.8095, implies moderate upside from the $97.74 anchor.
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.2.
What can break
Full-year 2026 guidance was reaffirmed rather than raised, leaving less room for execution slips if the commercial mix softens.
Momentum
60
Value
66
Sentiment
38
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $109.00 · Bull $120.00 · Bear $86.00
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-29 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $116.33
Why
Momentum60 · Δ7d -4.1
Value66 · Δ7d -0.2
Sentiment38 · Δ7d -3.6
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
60
26% active weight
Current posture
7d trendImproving
Δ7d
-4.1
Δ21d
-14.1
Value
66
39% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
-0.1
Sentiment
38
34% active weight
Current posture
7d trendSoftening
Δ7d
-3.6
Δ21d
-4.5
Why this grade

Composite grade B. Momentum 60.3 / Value 65.9 / Sentiment 38.5

Fundamentals (TTM)
As of 2026-07-21
Market Cap
$23.45B
Beta
0.83
Shares Out
199.78M
P/E (TTM)
17.2
P/S (TTM)
4.15
P/FCF (TTM)
16.69
Rev YoY
+20.9%
EPS YoY
+83.7%
Gross Margin
+91.2%
Op Margin
+30.8%
Net Debt
-$3.53B
Current Ratio
3.68
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology